Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Опыт клинического применения абиратерона ацетата в лечении больных кастрационно-резистентным раком предстательной железы
Опыт клинического применения абиратерона ацетата в лечении больных кастрационно-резистентным раком предстательной железы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Недавние рандомизированные исследования III фазы по оценке эффективности абиратерона ацетата у больных метастатическим кастрационно-резистентным раком предстательной железы (КРРПЖ), как сразу после регистрации кастрационной резистентности, так и после прогрессии на доцетакселе, показали значительное увеличение времени до радиографической прогрессии и общей выживаемости, в том числе у пациентов с наличием выраженного болевого синдрома, высоким уровнем простатоспецифического антигена и висцеральными метастазами. В данной статье мы представляем собственный опыт применения абиратерона ацетата у больных метастатическим КРРПЖ c наличием неблагоприятных факторов прогноза выживаемости. В исследование вошли 25 пациентов с метастатическим КРРПЖ, получавших терапию абиратероном.
Ключевые слова: абиратерона ацетат, кастрационно-резистентный рак предстательной железы.
Key words: abiraterone acetate, castration-resistant prostate cancer.
Ключевые слова: абиратерона ацетат, кастрационно-резистентный рак предстательной железы.
________________________________________________
Key words: abiraterone acetate, castration-resistant prostate cancer.
Полный текст
Список литературы
1. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154–79.
2. Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clin Cancer Res 2009; 15: 39–47.
3. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–59.
4. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–12.
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–20.
6. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68.
7. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431–8.
8. Engel-Nitz NM, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011; 3: 233–45.
9. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706–8.
10. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–22.
11. Mottet N et al. Guidelines on prostate cancer. Eur Urol 2014; 65 (1): 124–37; Eur Urol 2014; 65 (2): 467–79.
12. Berthold DR et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival Analysis in the TAX 327 study. J Clin Oncol 2008; 26: 242–5.
13. Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742–8.
14. Attard G, Reid AH, De Bono JS. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28 (29): e560–e561.
15. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563–71.
16. Danila DC, Morris MJ, De Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496–501.
17. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489–95.
18. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481–8.
19. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.
20. Fizazi K, Scher HI, Molina A. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13 (Issue 10): 983–99.
21. Ryan CJ, Smith MR, De Bono JS. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; 368 (2): 138–48.
22. Jr Goodman OB et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant cancer. Prostate Cаncer Prostatic Dis 2014; 17: 34–9.
23. Rathkopf DE. Genitourinary Cancers Symposium. J Clin Oncol 2013; 31 (Suppl. 6): 5.
2. Snoek R, Cheng H, Margiotti K et al. In vivo knockdown of the Androgen Receptor Results in Growth Inhibition and Regression of Well-Established, Castration-Resistant Prostate Tumors. Clin Cancer Res 2009; 15: 39–47.
3. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–59.
4. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–12.
5. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513–20.
6. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68.
7. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431–8.
8. Engel-Nitz NM, Alemayehu B, Parry D, Nathan F. Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res 2011; 3: 233–45.
9. Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C. A population-based study of prostate cancer chemotherapy. Clin Oncol (R Coll Radiol) 2011; 23: 706–8.
10. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–22.
11. Mottet N et al. Guidelines on prostate cancer. Eur Urol 2014; 65 (1): 124–37; Eur Urol 2014; 65 (2): 467–79.
12. Berthold DR et al. Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival Analysis in the TAX 327 study. J Clin Oncol 2008; 26: 242–5.
13. Attard G, Reid AH, A’Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742–8.
14. Attard G, Reid AH, De Bono JS. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28 (29): e560–e561.
15. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563–71.
16. Danila DC, Morris MJ, De Bono JS et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496–501.
17. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489–95.
18. Ryan CJ, Smith MR, Fong L et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481–8.
19. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005.
20. Fizazi K, Scher HI, Molina A. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13 (Issue 10): 983–99.
21. Ryan CJ, Smith MR, De Bono JS. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med 2013; 368 (2): 138–48.
22. Jr Goodman OB et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant cancer. Prostate Cаncer Prostatic Dis 2014; 17: 34–9.
23. Rathkopf DE. Genitourinary Cancers Symposium. J Clin Oncol 2013; 31 (Suppl. 6): 5.
Авторы
Я.В.Гриднева1, В.Б.Матвеев1, Д.З.Купчан1, С.А.Калинин2, М.В.Петерс3
1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва;
2 ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва;
3 ГБОУ ДПО РМАПО Минздрава России, Москва
1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва;
2 ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва;
3 ГБОУ ДПО РМАПО Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.